Impact of Order Set Implementation on Institutional Management of Clostridioides difficile in Adult Patients
2024
- 4Usage
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Usage4
- Abstract Views4
Poster Description
In February 2022, the University of Rochester Medical Center (URMC) updated their practice guidelines, in accordance with the Infectious Diseases Society of America, to include fidaxomicin as the preferred agent in patients with initial (non-fulminant) or first recurrence of C. difficile infection (CDI).Health system protocols were updated to include polymerase chain reaction (PCR) testing for patients with suspected CDI followed by confirmation via toxin enzyme immunoassay (EIA).In the appropriate clinical context, PCR+/EIA+ test confirms active CDI and warrants antibiotic treatment.PCR+/EIA- test indicates likely colonization and may preclude the need for treatment.A CDI order set was implemented in May 2023 to facilitate guideline adherence
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know